In another study, the cancer cell line JIMT1-TM showed long-term resistance to the drug after repeated administration of anti-human epidermal growth factor receptor 2 (anti-HER2) transtuzumab maytansinoid, as the level of HER2 protein decreased (Loganzo et al., 2015). The gene discussed is ERBB2; the disease is cancer.